![Chris Rallis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chris Rallis
Director/Board Member at
FENNEC PHARMACEUTICALS INC.
Net worth: 678 078 $ as of 2026-06-29
Profile
Chris A. Rallis is currently an Independent Director at Fennec Pharmaceuticals, Inc. since 2011 and a Director at Salisbury School, Inc. Former roles include President & Chief Executive Officer at ImmunoBiosciences, Inc. from 2006 to 2007, Independent Director at Tenax Therapeutics, Inc. from 2011 to 2021, President, Chief Operating Officer & Director at Triangle Pharmaceuticals, Inc. from 1995 to 2003, and Director positions at Incara Pharmaceuticals Corp., Soligenix, Inc., EMD Millipore Corp., Lee's Pharmaceutical Holdings Ltd., Naicons Srl, Aeolus Pharmaceuticals, Inc., Lung Cancer Initiative, and Vice President of Strategic Planning & Business Development at Burroughs Wellcome.
Education includes graduate studies at Duke University and undergraduate studies at Harvard College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-09 | 63,077 ( 0.18% ) | 678 078 $ | 2026-06-29 |
Chris Rallis active positions
| Companies | Position | Start |
|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Director/Board Member | 2011-08-24 |
Salisbury School, Inc. | Director/Board Member | - |
Former positions of Chris Rallis
| Companies | Position | End |
|---|---|---|
| TENAX THERAPEUTICS, INC. | Director/Board Member | 2021-06-09 |
ImmunoBiosciences, Inc.
 ImmunoBiosciences, Inc. Packaged SoftwareTechnology Services Develops a vaccine platform technology solution to create vaccines to combat diseases | Chief Executive Officer | 2007-05-31 |
Incara Pharmaceuticals Corp.
 Incara Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cardiovascular and pulmonary diseases | Director/Board Member | 2004-08-08 |
Triangle Pharmaceuticals, Inc.
 Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops antiviral drug candidates | President | 2002-12-31 |
Lung Cancer Initiative
 Lung Cancer Initiative Miscellaneous Commercial ServicesCommercial Services Lung Cancer Initiative is a nonprofit organization dedicated to improving the lives of those affected by lung cancer through research funding, education, survivorship support, and access to care programs. The private company is located in the US. The organization invests in lung cancer research, particularly supporting early-career investigators through grants and fellowships to advance diagnosis, treatment, and understanding of lung cancer biology. It collaborates with professional societies and research institutions, provides educational resources for patients, caregivers, and healthcare professionals, and offers patient support programs such as transportation assistance, financial aid, therapy assistance, and peer-to-peer emotional support. Lung Cancer Initiative also hosts community engagement events, survivor programs, and wellness retreats to enhance quality of life and build a supportive lung cancer community. | Director/Board Member | - |
Training of Chris Rallis
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
44
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Soligenix, Inc.
 Soligenix, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and commercializes biodefense vaccines and oral therapeutic products | Health Technology |
EMD Millipore Corp.
 EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services Engages in research, development and production of biotechnology & pharmaceutical drug therapies | Commercial Services |
Tenax Therapeutics, Inc.
 Tenax Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes pharmaceutical therapeutic products | Health Technology |
Triangle Pharmaceuticals, Inc.
Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops antiviral drug candidates | Commercial Services |
Incara Pharmaceuticals Corp.
Incara Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cardiovascular and pulmonary diseases | Health Technology |
Fennec Pharmaceuticals, Inc.
 Fennec Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutic products which dedicated to improving the lives of children with cancer who experience hearing loss | Health Technology |
Lee's Pharmaceutical Holdings Ltd.
 Lee's Pharmaceutical Holdings Ltd. Pharmaceuticals: MajorHealth Technology Engages in the drug development, clinical development, regulatory, manufacturing, selling and marketing of pharmaceutical products | Health Technology |
ImmunoBiosciences, Inc.
ImmunoBiosciences, Inc. Packaged SoftwareTechnology Services Develops a vaccine platform technology solution to create vaccines to combat diseases | Technology Services |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aeolus Pharmaceuticals, Inc.
 Aeolus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs | Health Technology |
Burroughs Wellcome | |
Salisbury School, Inc. | |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Naicons Srl
 Naicons Srl Packaged SoftwareTechnology Services Develops game-changing drug discovery platform | Technology Services |
Lung Cancer Initiative
Lung Cancer Initiative Miscellaneous Commercial ServicesCommercial Services Lung Cancer Initiative is a nonprofit organization dedicated to improving the lives of those affected by lung cancer through research funding, education, survivorship support, and access to care programs. The private company is located in the US. The organization invests in lung cancer research, particularly supporting early-career investigators through grants and fellowships to advance diagnosis, treatment, and understanding of lung cancer biology. It collaborates with professional societies and research institutions, provides educational resources for patients, caregivers, and healthcare professionals, and offers patient support programs such as transportation assistance, financial aid, therapy assistance, and peer-to-peer emotional support. Lung Cancer Initiative also hosts community engagement events, survivor programs, and wellness retreats to enhance quality of life and build a supportive lung cancer community. | Commercial Services |
- Stock Market
- Insiders
- Chris Rallis
